Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine
Phase 2RecruitingDevelopment Stage
T-cell Acute Lymphoblastic Leukemia
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Dec 27, 2024 → Dec 1, 2033
About Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine
Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + Thioguanine is a phase 2 stage product being developed by AbbVie for T-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06390319. Target conditions include T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06390319 | Phase 2 | Recruiting |
Competing Products
20 competing products in T-cell Acute Lymphoblastic Leukemia